The closing price of Opko Health Inc (NASDAQ: OPK) was $0.93 for the day, down -6.51% from the previous closing price of $1.00. In other words, the price has decreased by -$0.0651 from its previous closing price. On the day, 15517921 shares were traded.
Ratios:
Our analysis of OPK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.22 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.20.
On December 15, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 28 when FROST PHILLIP MD ET AL bought 500,000 shares for $0.99 per share. The transaction valued at 496,150 led to the insider holds 208,868,225 shares of the business.
FROST PHILLIP MD ET AL bought 1,000,000 shares of OPK for $991,700 on Feb 21. The CEO & Chairman now owns 208,368,225 shares after completing the transaction at $0.99 per share. On Feb 07, another insider, FROST PHILLIP MD ET AL, who serves as the CEO & Chairman of the company, bought 1,500,000 shares for $0.98 each. As a result, the insider paid 1,462,800 and bolstered with 207,368,225 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OPK now has a Market Capitalization of 655.17M and an Enterprise Value of 885.86M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.75 while its Price-to-Book (P/B) ratio in mrq is 0.52. Its current Enterprise Value per Revenue stands at 1.03 whereas that against EBITDA is -13.52.
Stock Price History:
Over the past 52 weeks, OPK has reached a high of $2.24, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 1.0992, while the 200-Day Moving Average is calculated to be 1.4928.
Shares Statistics:
OPK traded an average of 11.88M shares per day over the past three months and 9.22M shares per day over the past ten days. A total of 773.28M shares are outstanding, with a floating share count of 365.96M. Insiders hold about 47.49% of the company’s shares, while institutions hold 27.25% stake in the company. Shares short for OPK as of Feb 15, 2024 were 97.94M with a Short Ratio of 8.25, compared to 98.61M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.05% and a Short% of Float of 26.94%.
Earnings Estimates
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.14, while EPS last year was -$0.02. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.28 and -$0.57 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.25, with 5 analysts recommending between -$0.02 and -$0.53.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $184.8M to a low estimate of $181.88M. As of the current estimate, Opko Health Inc’s year-ago sales were $237.6M, an estimated decrease of -22.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $191.12M, a decrease of -5.40% over than the figure of -$22.80% in the same quarter last year. There is a high estimate of $196.5M for the next quarter, whereas the lowest estimate is $184.94M.
A total of 6 analysts have provided revenue estimates for OPK’s current fiscal year. The highest revenue estimate was $790.05M, while the lowest revenue estimate was $750.5M, resulting in an average revenue estimate of $772.48M. In the same quarter a year ago, actual revenue was $863.5M, down -10.50% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $847.29M in the next fiscal year. The high estimate is $916.23M and the low estimate is $810.7M. The average revenue growth estimate for next year is up 9.70% from the average revenue estimate for this year.
